Bass and Spangenberg target another pharma company through IPR
UPDATED APRIL 7 TO INCLUDE NEW IPR: Hayman Capital’s Kyle Bass and IP Nav’s Erich Spangenberg have targeted a second and third pharmaceutical company at the PTAB, filing inter partes review petitions challenging patents owned by Shire and Jazz
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: